The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Deep Vein Thrombosis Market Between 2026 And 2030?
The deep vein thrombosis market has shown consistent expansion recently. It is forecast to grow from $1.09 billion in 2025 to $1.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.0%. Factors driving this historical growth include an increasing incidence of venous thromboembolism, an aging population with sedentary lifestyles, an uptick in hospital-based surgical procedures, broader access to conventional anticoagulants, and enhanced awareness of dvt complications.
The deep vein thrombosis market is projected for consistent expansion over the coming years, reaching $1.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.7%. This anticipated growth is driven by several factors, including the progress in new anticoagulant therapies, a rising preference for oral medications over injectable ones, the broadening of homecare and remote monitoring services, an increase in preventive screening initiatives, and enhanced accessibility via online pharmacies. Key trends expected during this period involve the increasing uptake of direct oral anticoagulants, a move towards managing deep vein thrombosis in outpatient and home settings, a greater emphasis on early diagnosis and categorizing risk, the growing application of minimally invasive interventional procedures, and the widening reach of online and specialized pharmacy platforms.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10616&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Deep Vein Thrombosis Market?
The deep vein thrombosis market is projected to expand due to the increasing count of individuals who require DVT treatment. This treatment involves administering medications, such as anticoagulants and other drugs, to patients with deep vein thrombosis, aiming to prevent the formation of new blood clots and inhibit existing ones from growing, thereby improving the disease condition. The rising number of patients needing DVT treatment indicates a higher prevalence of deep vein thrombosis, which in turn necessitates products for its diagnosis, prevention, and therapeutic management. For instance, in February 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported that approximately 900,000 people in the United States could be affected by deep vein thrombosis annually, and between 60,000 and 100,000 Americans die each year from DVT or PE (pulmonary embolism). Therefore, the growing number of individuals requiring deep vein thrombosis (DVT) treatment is a key driver for the market.
Which Market Segments Are Examined In The Deep Vein Thrombosis Market Study?
The deep vein thrombosis market covered in this report is segmented –
1) By Drug Class: Anticoagulants, Inferior Vena Cava Filters, Other Drug Class
2) By Treatment: Surgery, Drugs, Other Treatments
3) By Mode Of Administration: Injectable, Oral, Other Modes Of Action
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-users
Subsegments:
1) By Anticoagulants: Direct Oral Anticoagulants (DOACs), Vitamin K Antagonists, Low Molecular Weight Heparins, Unfractionated Heparin
2) By Inferior Vena Cava Filters: Retrievable IVC Filters, Permanent IVC Filters, Advanced IVC Filter Systems
3) By Other Drug Class: Thrombolytics, Antiplatelet Agents, Fibrinolytics, Combination Therapy
Which Trends Are Influencing The Deep Vein Thrombosis Market?
Leading businesses within the deep vein thrombosis market are prioritizing strategic collaborations to facilitate swift diagnosis of DVT and enhance their profitability. These alliances underscore an increasing focus on utilizing AI and machine learning to advance medical diagnostic capabilities, particularly for the quick and accurate detection of DVT. A notable example occurred in November 2023 when ThinkSono Ltd., a UK-based firm specializing in ultrasound AI for diagnosing deep vein thrombosis, joined forces with NYU Langone Health, a US-based academic medical center. Their collaboration initiated the inaugural clinical trial for novel artificial intelligence (AI)-powered ultrasound software designed for faster and more portable DVT diagnosis. This partnership leverages the ThinkSono Guidance System technology, which employs AI to potentially identify DVT with greater speed, accuracy, and cost-effectiveness than traditional methods. Researchers plan to apply the ThinkSono Guidance System alongside standard ultrasound scanning in patients, both those with and without DVT. The performance of these two diagnostic approaches will be compared to assess and validate the ThinkSono system’s accuracy. Additionally, medical students from the NYU Grossman School of Medicine will contribute to the trial’s execution as part of their practical research curriculum.
Who Are The Primary Competitors In The Deep Vein Thrombosis Market?
Major companies operating in the deep vein thrombosis market are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Shire Pharmaceuticals, AstraZeneca PLC, Endo International plc
Read the full deep vein thrombosis market report here:
https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report
What Are The Leading Geographic Regions In The Deep Vein Thrombosis Market?
North America was the largest region in the deep vein thrombosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Deep Vein Thrombosis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10616&type=smp
Browse Through More Reports Similar to the Global Deep Vein Thrombosis Market 2026, By The Business Research Company
Deep Vein Thrombosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report
Venous Thromboembolism Market Report 2026
https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report
Thrombophilia Market Report 2026
https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model